EUCTR2019-001209-26-FR进行中（未招募）1 期
Multicentre, randomized, controlled, open-label, multi-centre medico-economic study evaluating the efficacy of adding zoledronic acid to Stereotaxic radiotherapy in the treatment of vertebral metastases
INSTITUT DE CANCEROLOGIE DE L'OUEST0 个研究点目标入组 225 人开始时间: 2019年5月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 225
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 75
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Multicentre, randomized, controlled, open-label, multi-centre medicoeconomic study evaluating the efficacy of adding zoledronic acid or denosumab to Stereotaxic radiotherapy in the treatment of vertebral metastases (ZOSTER)Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapyMedDRA version: 21.1Level: LLTClassification code: 10049038Term: Metastatic bone pain Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10027484Term: Metastatic pain Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10027474Term: Metastatic Class: 10029104CTIS2024-513248-27-00Institut De Cancerologie De L Ouest202
招募中
1 期
Multicentre, open-label, randomized, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer (PelvEx II)ocally recurrent rectal cancerMedDRA version: 21.0Level: PTClassification code: 10038046Term: Rectal cancer recurrent Class: 100000004864CTIS2024-512526-28-00Catharina Ziekenhuis Stichting364
进行中（未招募）
1 期
Multicentre, randomised, controlled, open-label, study comparing the efficacy and safety of slow repeated intravenous infusions of 2 doses of Doxorubicin Transdrug™ (DT) (20 mg/m² or 30 mg/m²) to those of best standard of care (BSC) in patients with advanced hepatocellular carcinoma (HCC) after failure or intolerance to sorafenib - ReLive Study - ReLiveEUCTR2011-002843-92-ITBioAlliance Pharma397
进行中（未招募）
1 期
Study comparing the efficacy and safety of doxorubicin Transdrug™ administered intravenously to the best available treatment in patient suffering from liver cancer after treatment with sorafenib.EUCTR2011-002843-92-HUOnxeo390
进行中（未招募）
1 期
Study comparing the efficacy and safety of doxorubicin Transdrug™ administered intravenously to the best available treatment in patient suffering from liver cancer after treatment with sorafenib.Advanced Hepatocellular Carcinoma (HCC)EUCTR2011-002843-92-ATOnxeo390